Clinical Trials Logo
  1. Home
  2. Colon Cancer Liver Metastasis
  3. NCT03310008

Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases — SHRINK  

Colon Cancer Liver Metastasis Clinical Trial

Official title:
An Open-label, Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2, Administered Concurrently With the Neoadjuvant FOLFOX Treatment in Patients With Potentially Resectable Liver Metastases From Colorectal Cancer

Clinical Trial Summary

SHRINK (Standard cHemotherapy Regimen and Immunotherapy with NKR-2) is an open-label Phase I study to assess the safety and clinical activity of multiple administrations of autologous NKR-2 cells administered concurrently with a standard chemotherapy treatment (FOLFOX) in potentially resectable liver metastases from colorectal cancer.

The trial will test three dose levels. At each dose, the patients will receive three successive administrations, two weeks apart, NKR-2 cells. The study will enroll up to 36 patients (dose escalation and expansion phases).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03310008
Study type Interventional
Source Celyad Oncology SA
Contact
Status Active, not recruiting
Phase Phase 1
Start date August 7, 2017
Completion date May 2021
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT01540435 - Perioperative Treatment of Resectable Liver Metastases Phase 2
Terminated NCT01464593 - Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC) Phase 2
Completed NCT02090816 - Combined Liver and Right Lung Resection for Colorectal Metastases by Means of J-shaped Thoracophrenolaparotomy N/A
Recruiting NCT04682665 - Prebiotic Effect of Eicosapentaenoic Acid Treatment for Colorectal Cancer Liver Metastases
Completed NCT01730365 - Optical Detection of Malignancy During Percutaneous Interventions N/A
Completed NCT01526200 - Contrast-Enhanced Intraoperative Ultrasound During Liver Surgery for Colorectal Cancer Liver Metastases N/A
Terminated NCT03370198 - Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer Phase 1
Completed NCT02781935 - Diffusion-Weighted MRI for Liver Metastasis
Completed NCT01891552 - Observational Study on Second Line Treatment of Liver Metastases With DEBIRI and Cetuximab N/A
Recruiting NCT05293041 - Argipressin's Influence on Blood Loss During Hepatic Resection Phase 4
Recruiting NCT02631564 - Safety of TACE With Oxaliplatin, Irinotecan and Raltitrexed for Refractory Colorectal Cancer Liver Metastasis N/A
Recruiting NCT03175016 - Irinotecan-Eluting Bead (DEBIRI) for Patients With Liver Metastases From Colorectal Cancer Phase 2/Phase 3
Recruiting NCT02363049 - Colectomy in Patients With Asymptomatic and Unresectable Stage IV Colon Cancer Phase 3
Recruiting NCT02557490 - Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases Phase 4
Completed NCT03415126 - A Study of ASN007 in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04668872 - Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
Completed NCT01522209 - Detection Rate of Liver Metastases With Contrast Enhanced Intraoperative Ultrasound Compared to Regular Imaging N/A